

Anti 2019-nCoV Spike Protein Llama heavy-chain Antibody (NBX20010)

Catalog No: C19S1-641HL

SARS-CoV-2 expresses surface spike proteins or S proteins that bind to the angiotensin-converting enzyme-2 (ACE2) receptors to gain entry into the human host cells. The body produces monoclonal neutralizing antibodies to block this binding, but recent mutations on the ever-evolving S protein of the virus is successful in evading this immune response. VHH antibodies, are minimal and monomeric antigen-binding domains derived from llama antibodies and can be bioengineered to have excellent epitope specificity and anti-SARS-CoV-2 neutralizing potential. SignalChem's recombinant VHH-Human IgG Antibody raised in llama for studying neutralization of SARS-CoV-2 and detection of 2019-nCoV Spike Protein.

Unique Selling Points



Detects 2019 n-CoV Spike Protein Neutralizing activity validated for wild type strain

🗲 Stratech

stratech.co.uk/signalchem info@stratech.co.uk







Fully functional antibody

Neutralizing activity validated for N501Y variant RBD.

Assay Data



Binding ability measured in a functional ELISA. Anti 2019-nCoV Spike Protein Neutralizing Nanobody (C19S1-641HL) binds 2019-nCoV RBD.



Immobilized Anti 2019-nCoV Spike Protein Llama heavy-chain (C19S1-641HL) binds 2019-nCoV Spike protein RBD that can be detected at picomol level using Anti 2019-nCoV Spike Protein hlgG Antibody.